MDGL News and Press, Madrigal Pharmaceuticals Inc. From 05/06/24

2024-05-06 10:57:03 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...

2024-04-30 16:30:23 ET Summary MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide, but there is potential for combination therapy t...

CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. H...

2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...

2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...

CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Mad...

2024-04-23 06:30:13 ET Bank of America Securities analyst issues UNDERPERFORM recommendation for MDGL on April 22, 2024 06:15AM ET. MDGL was trading at $213.49 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations ar...

2024-04-22 11:18:39 ET Summary The Simplify Propel Opportunities ETF (SURI) is a healthcare-based fund that provides exposure to global fixed income and equity markets in the healthcare sector. SURI has a since-inception return of -13%, but its recent performance has shown potenti...

(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...

2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...